Income statement, balance sheet and cash flow statement for the last 6 fiscal years, taken from the XBRL data Evotec SE files with the SEC in its annual reports.
In EUR millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2019
FY2021
FY2021
FY2022
FY2023
FY2024
Revenue
446
501
618
751
781
797
Cost of revenue
314
375
466
577
606
682
Gross profit
133
126
152
174
175
115
Research and development
58.4
63.9
72.2
76.6
68.5
50.9
Selling, general and administrative
66.4
77.2
105
156
170
188
Operating income
62.7
48.6
41
20.9
-47.5
-143
Pre-tax income
56.7
25.8
237
-154
-80.6
-194
Income tax
19.4
19.6
21.5
21.7
3.32
2.1
Net income to minority interests
-0.84
Net income
38.2
6.28
216
-176
-83.9
-196
EPS, basic
0.25
0.04
1.30
-0.99
-0.47
-1.11
EPS, diluted
0.25
0.04
1.30
-0.99
-0.47
-1.11
Balance sheet
FY2019
FY2021
FY2021
FY2022
FY2023
FY2024
Cash and equivalents
277
423
699
415
511
306
Short-term investments
59.4
159
303
93.2
90.4
Receivables
172
98.4
116
Inventory
13.6
25.8
29.8
30.9
31.1
Total current assets
659
1,101
1,074
903
682
Property, plant and equipment
239
337
485
650
Lease right-of-use assets
142
145
168
Goodwill
256
247
258
275
276
283
Intangible assets
117
98
30.9
23.8
15.5
26.4
Total assets
1,462
2,235
2,257
2,252
1,913
Accounts payable
97.3
134
85.8
Short-term debt
1.56
130
27.1
Total current liabilities
208
325
338
465
345
Lease liabilities
131
136
162
170
132
Total liabilities
738
857
1,070
1,133
960
Total debt
362
330
437
288
Retained earnings
-433
-216
-392
-476
-672
Shareholders' equity
724
1,378
1,187
1,120
953
Total equity
479
724
1,378
1,187
1,120
953
Total liabilities and equity
1,462
2,235
2,257
2,252
1,913
Cash flow statement
FY2019
FY2021
FY2021
FY2022
FY2023
FY2024
Net income
37.3
6.28
216
-176
-83.9
-196
Cash from operations
42.2
44.7
127
206
36.4
18.2
Capital expenditures
-31.3
-99.1
-119
-181
-213
-117
Cash from investing
-86.6
-155
-243
-413
-13.3
-71.2
Debt issued
292
21.5
30.8
220
0.9
Debt repaid
-70
-6.52
-16
-34.1
-113
-129
Stock issued
250
403
0.36
Cash from financing
211
246
393
-58.1
72
-161
Exchange rate effect
1.13
9.51
-0.07
-19
0.64
9.87
Free cash flow
10.9
-54.4
7.66
24.5
-177
-99.2
Interest paid
4.49
3.47
5.43
9.8
Income taxes paid
-6.03
18.5
12.9
-76.1
Key metrics
Worked out from the statements above. Latest values use fiscal 2024. No valuation: the share price is quoted in a different currency than the statements.
Profitability
Metric
Value
How it is calculated
Gross margin
14.4%
Gross profit / revenue.
Operating margin
-17.9%
Operating income / revenue.
Pre-tax margin
-24.3%
Pre-tax income / revenue.
Net margin
-24.6%
Net income / revenue.
FCF margin
-12.5%
Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin
2.3%
Cash from operations / revenue.
Return on equity (ROE)
-18.9%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-9.4%
Net income / average total assets.
Return on invested capital (ROIC)
-11.4%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
R&D / revenue
6.4%
Research and development expense / revenue.
SG&A / revenue
23.6%
Selling, general and administrative expense / revenue.
Capex / revenue
14.7%
Capital expenditures / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
2.0%
Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y
8.8%
Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Revenue CAGR, 5y
12.3%
Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Gross profit growth, 1y
-34.4%
Gross profit vs the same period a year earlier. Only from a positive base.
Gross profit CAGR, 3y
-8.8%
Compound annual growth of gross profit over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Gross profit CAGR, 5y
-2.9%
Compound annual growth of gross profit over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Operating cash flow growth, 1y
-50.0%
Operating cash flow vs the same period a year earlier. Only from a positive base.
Operating cash flow CAGR, 3y
-47.6%
Compound annual growth of operating cash flow over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Operating cash flow CAGR, 5y
-15.5%
Compound annual growth of operating cash flow over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Book value growth, 1y
-14.9%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y
-11.6%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets growth, 1y
-15.1%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
-5.1%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
1.98x
Current assets / current liabilities.
Quick ratio
1.49x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
1.15x
(Cash + short-term investments) / current liabilities.
Debt / equity
0.30x
Total debt / shareholders' equity. Not shown when equity is negative.
Debt / assets
15.0%
Total debt / total assets.
Liabilities / assets
50.2%
Total liabilities / total assets.
Net debt
-€109.2M
Total debt - cash - short-term investments. Negative means more cash than debt.
Days inventory + days sales outstanding - days payables.
Capex / operating cash flow
644.7%
Capital expenditures / cash from operations, when that is positive.
Per share
Metric
Value
How it is calculated
EPS, diluted
-€1.11
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
EPS, basic
-€1.11
Net income per basic share, as reported (split-adjusted).
What was Evotec SE's revenue in fiscal 2024?
Evotec SE reported revenue of €797.0M for fiscal 2024, 2% higher than the year before.
Was Evotec SE profitable in fiscal 2024?
No. It reported a net loss of €196.1M.
How much free cash flow did Evotec SE generate in fiscal 2024?
Cash from operations of €18.2M minus capital expenditures of €117.5M left free cash flow of -€99.2M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.